```
=> d his

     (FILE 'HOME' ENTERED AT 15:27:48 ON 13 APR 2001)

     FILE 'USPATFULL' ENTERED AT 15:28:00 ON 13 APR 2001
L1            14 S TESTOSERONE
L2         72044 S SEX? OR DYSFUNCTION OR ERECT? OR IMPOTEN?
L3             1 S L1(S)L2

     FILE 'PCTFULL, EUROPATFULL' ENTERED AT 15:31:14 ON 13 APR 2001
L4             0 S L3
L5             2 S L1

     FILE 'USPATFULL' ENTERED AT 15:32:26 ON 13 APR 2001
L6          3626 S TESTOSTERONE
L7           648 S L6(S)L2
L8         43033 S ERECT? OR IMPOTEN?
L9            90 S L6(S)L8

     FILE 'USPATFULL' ENTERED AT 16:37:42 ON 13 APR 2001
L10           35 S SILDENAFIL
L11            2 S L10(S)(TOPICAL? OR TRANSDERMAL?)

     FILE 'PCTFULL, EUROPATFULL' ENTERED AT 16:41:33 ON 13 APR 2001
L12           12 S L11
```

limitation, **sildenafil**, alprostadil, papaverine, minoxidil, prostaglandins, such as prostaglandin E2 (see, e.g., U.S. Patent 5,708,031 for formulations of prostaglandins useful for **topical** application to the penis), organic nitrites (see, e.g., U.S. Patent 5,646,181 for useful organic nitrites and formulations thereof), inhibitors of the renin-angiotensin. . .

L12 ANSWER 11 OF 12 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1999002161 PCTFULL
TITLE (ENGLISH): USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES
TITLE (FRENCH): UTILISATION D'INHIBITEURS DE LA PHOSPHORDIESTERASE DANS LE TRAITEMENT DE MALADIES DE LA PROSTATE
INVENTOR(S): STIEF, Christian, Georg; TRUSS, Michael, Carsten; UeCKERT, Stefan; JONAS, Udo
PATENT ASSIGNEE(S): FORSSMANN, Wolf-Georg
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9902161	A1	19990121

DESIGNATED STATES: AU CA US
APPLICATION INFO.: WO 1997-EP3617 19970709

DETD Example 2 - Solution for **Topical** Administration
From 500 mg of **sildenafil**, 2 ml of isopropyl myristate and 10 ml of ethanol, a solution for **topical** administration is prepared and packed in unit doses of 2 ml each.

L12 ANSWER 12 OF 12 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1080719 EUROPATFULL EW 200110 FS OS
TITLE: Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids.
Verfahren zur Potenzierung der Wirksamkeit topischer Wirkstoffe durch Mono-acyl-(lyso)-glycerophospholipide.
Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids.
INVENTOR(S): Bishop, Michael, 9400 Rockbrook Dr., Dallas, Texas 75220, US;
Gillis, Glen, 1498 N. Mayhill Rd, Denton, Texas 76208, US;
Norton, Scott J., 1105 Thornridge Ct., Argyle, Texas 76226, US
PATENT ASSIGNEE(S): Active Organics Inc., 1097 Yates St., Lewisville, Texas 75057, US

PATENT ASSIGNEE NO: 3108430
AGENT: Wagner, Karl H., Dipl.-Ing., WAGNER & GEYER
Patentanwaelte Gewuerzmuehlstrasse 5, 80538 Muenchen,
DE
AGENT NUMBER: 12561
OTHER SOURCE: BEPA2001017 EP 1080719 A2 0024
SOURCE: Wila-EPZ-2001-H10-T1b
DOCUMENT TYPE: Patent
LANGUAGE:

L12 ANSWER 10 OF 12 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1999039763 PCTFULL
TITLE (ENGLISH): ULTRASOUND-MEDIATED DRUG DELIVERY
TITLE (FRENCH): ADMINISTRATION DE MEDICAMENTS PAR ULTRASONS
INVENTOR(S): ATALA, Anthony; MACHLOUF, Marcelle
PATENT ASSIGNEE(S): CHILDREN'S MEDICAL CENTER CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9939763	A1	19990812
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US2701		19990209
PRIORITY (ORIGINAL):	US 1998-60/074231		19980210
	US 1998-		19980713

DETD The **transdermal** application of vasoactive drugs for treatment of erectile dysfunction has been studied in vitro and in vivo. While **transdermal** application avoids certain of the disadvantages of injection, **transdermal** therapies to date have been associated with limited success. The side effects of **sildenafil** and other enzyme inhibitors, as well as, systemic vasoactive drugs could be diminished significantly, if a suitable **transdermal** delivery mechanism was available because the necessary doses could be lowers and the drugs would be less likely to affect remote body organs.

Transdermal administration of drugs, such as cortisone derivatives, **sildenafil**, papaverine and minoxidil (among others) can offer a safe, non-painful alternative to previously known therapies. However, conventional **transdermal** application of such drugs has met with reduced success, possibly due to the stratum corneum layer of the skin, which is resistant to drug. . .

Therapeutic agents useful for treatment of erectile dysfunction include, without

```
=> d his

     (FILE 'HOME' ENTERED AT 15:27:48 ON 13 APR 2001)

     FILE 'USPATFULL' ENTERED AT 15:28:00 ON 13 APR 2001
L1            14 S TESTOSERONE
L2         72044 S SEX? OR DYSFUNCTION OR ERECT? OR IMPOTEN?
L3             1 S L1(S)L2

     FILE 'PCTFULL, EUROPATFULL' ENTERED AT 15:31:14 ON 13 APR 2001
L4             0 S L3
L5             2 S L1

     FILE 'USPATFULL' ENTERED AT 15:32:26 ON 13 APR 2001
L6          3626 S TESTOSTERONE
L7           648 S L6(S)L2
L8         43033 S ERECT? OR IMPOTEN?
L9            90 S L6(S)L8
```

L9 ANSWER 50 OF 90 USPATFULL
ACCESSION NUMBER: 1998:30702 USPATFULL
TITLE: Medication for impotence containing lyophilized roe and
a powdered extract of Ginkgo biloba
INVENTOR(S): Omar, Lotfy Ismail, P.O. Box F396, Kew Gardens, NY, United States 11415

	NUMBER	DATE
PATENT INFORMATION:	US 5730987	19980324
APPLICATION INFO.:	US 1996-660875	19960610 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Kerr, Janet M.
LEGAL REPRESENTATIVE: Kroll, Michael I.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 478

SUMM **Testosterone** and its derivatives are obtained only by prescription. They are available as injection, oral, buccal tablets or other pharmaceutical dosage forms; the main use is for hypogonadism, male climactric and **impotence**. **Testosterone** also has other applications in medicine. As with other hormonal treatments, during administration of exogenous **testosterone**, endogenous **testosterone** release is inhibited through the negative feedback mechanism of the pituitary lutenizing hormone (LH.)

CLM What is claimed is:
8. The composition for treating **impotence** in human males according to claim 6, wherein said hormone is **testosterone** or a derivative thereof.

L9 ANSWER 45 OF 90 USPATFULL

ACCESSION NUMBER: 1998:75173 USPATFULL

TITLE: Treatment of erectile dysfunction

INVENTOR(S): Place, Virgil A., Kawaihae, HI, United States
Gale, Robert M., Los Altos, CA, United States
Berggren, Randall G., Livermore, CA, United States

PATENT ASSIGNEE(S): Vivus, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5773020	19980630
APPLICATION INFO.:	US 1997-959739	19971028 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-486727, filed on 7 Jun 1995, now abandoned which is a division of Ser. No. US 1993-93545, filed on 19 Jul 1993, now patented, Pat. No. US 5474535 which is a division of Ser. No. US 1991-787306, filed on 30 Oct 1991, now patented, Pat. No. US 5242391 which is a continuation-in-part of Ser. No. US 1990-514397, filed on 25 Apr 1990, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Azpuru, Carlos

LEGAL REPRESENTATIVE: Reed, Dianne E.Bozicevic & Reed, LLP

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 1119

SUMM . . . the relatively innocuous intervention involved and the high failure rate of penile prostheses, the pharmacological approach to the treatment of **impotence** is still quite advantageous to a large number of patients and could be even more so if the side effects. . . vasodilators via the male urethra has been disclosed in Voss, U.S. Pat. No. 4,801,587 and Kock, EPA 0357581 to produce **erections** as has the transurethral administration of **testosterone**, S. M. Milco, Bulletins et Memoirs de la Societa Roumaine D'Endocrinologie, Vol. 5, pp 434-437 (December 1939), strychnine and another drug (citation to be provided). It has also been suggested that cocaine administered transurethrally could contribute to an **erection** although the reported side effects were catastrophic, JAMA, Vol. 259, No. 21, page 3176 (1988).

DETD In its broadest aspect, this invention contemplates the treatment of **erectile** dysfunction by the transurethral administration of an agent, therapeutically effective with respect to the dysfunction, directly into the blood supplying the corpus cavernosum via the cross circulation with the spongiosa surrounding the urethra. The **erectile** dysfunctions which may be so treated include **impotence**, for which the therapeutic agent is one or more drugs capable of producing a vaso-dilatory or other **erection** inducing effect. Suitable vaso-dilatory agents include nitrates such as nitroglycerin and isosorbide dinitrate, long and short acting .alpha.-blockers such as. . . and enprostil, for example, prostaglandin E.sub.2, minoxidil, vasoactive intestinal peptides or any other agent which is capable of producing an **erection** when administered transurethrally. For example, dopamine agonists such as apomorphine and bromocriptine, **testosterone**, cocaine,

strychnine, and opioid antagonists such as naltrexone have been reported to induce **erection** and they may also be useful according to this invention. See S. Lal et al, Apomorphine: Clinical Studies on **Erectile Impotence** and Yawning, Prog. Neuro-Psychopharmacology, Vol. 13, 1989, pp 329-339 and A. Fabbri et al, Endorphins in Male **Impotence**. Evidence for Naltrexone Stimulation of **Erectile** Activity in Patient Therapy, Psychoneuroendocrinology, Vol. 14, No. 1 & 2, pp 89, 103-111.